Micardis (telmisartan) can now be prescribed for the prevention of cardiovascular morbidity in patients with manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke or peripheral arterial disease), or type 2 diabetes with documented target organ damage.
The recommended dose for this indication is 80mg once daily.
Further information: Boehringer Ingelheim